HemaQuest Pharma Adds $4 Million
HemaQuest Pharmaceuticals, a Newton, Mass.-based developer of small-molecule therapeutics to treat serious blood disorders, has raised $4 million in new Series B funding from Latterell Venture Partners. The company previously held a $12 million first close on the round, from Aberdare Ventures (lead), De Novo Ventures, Forward Ventures and Lilly Ventures. It has now raised a total of $36 million.
29 July 2010•2 mins read
